title: Effects of combination treatment with dipeptidyl peptidase IV inhibitor and sulfonylurea on glucose levels in rats.
abstract: The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarbonitrile), and glibenclamide on the glycemic responses to glucose loading in rats. Treatment with K579 inhibited the plasma DPP-IV activity even 8 h after the administration. K579 significantly suppressed the blood glucose elevation in glibenclamide-pretreated rats without excessive hypoglycemia. These profiles of K579 indicate that it could be useful agent to correct the postprandial glucose excursion in type 2 diabetes patients by combination treatment with glibenclamide.
authors.affiliation: Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan. kotaro.takasaki@kyowa.co.jp
authors.forename: Kotaro
authors.initials: K
authors.lastname: Takasaki
authors.forename: Takao
authors.initials: T
authors.lastname: Nakajima
authors.forename: Kimihisa
authors.initials: K
authors.lastname: Ueno
authors.forename: Yuji
authors.initials: Y
authors.lastname: Nomoto
authors.forename: Katsuya
authors.initials: K
authors.lastname: Higo
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D005905:Glyburide / Q000494:pharmacology; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013453:Sulfonylurea Compounds / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D011480:Protease Inhibitors; D013453:Sulfonylurea Compounds; D018819:Dipeptidyl Peptidase 4; D005905:Glyburide